Olezarsen · Tryngolza

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Hypertriglyceridemia · Phase 3 · investigational in the US

Also approved (2)
CA
  • Adjunct to diet in adult patients for the treatment of FCS (Notice of Compliance date from the CDA-AMC review; sponsor Theratechnologies Inc.)
Product first approved 2025canjhealthtechnol.ca
EU
  • Adjunct to diet in adults with genetically confirmed familial chylomicronemia syndrome; marketing authorisation holder Swedish Orphan Biovitrum AB (Sobi)
Product first approved 2025EMA

Company guidance: regulatory decision expected fourth quarter of 2026 (Ionis Pharmaceuticals, 9 Nov 2026). “FCS launch outside the U.S. underway; received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for sHTG (sHTG fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]), paving the way to bring TRYNGOLZA to sHTG patients across Europe with a final approval decision expected in the fourth quarter of 2026” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Familial Chylomicronemia Syndrome
NCT07727538 · Ionis Pharmaceuticals, Inc.
2026-07-31 – 2031-08 · Familial Chylomicronemia Syndrome
What this study did
NCT05130450 · Ionis Pharmaceuticals, Inc.
2021-11-18 – 2028-02 · Familial Chylomicronemia Syndrome
What this study did
NCT05185843 · Ionis Pharmaceuticals, Inc.
2022-02-25 – 2027-06 · Familial Chylomicronemia Syndrome
What this study did
Severe Hypertriglyceridemia
NCT05681351 · Ionis Pharmaceuticals, Inc.
2022-12-13 – 2027-03 · Severe Hypertriglyceridemia
What this study did
Phase 2 (2)
Hypertriglyceridemia
NCT03385239 · Akcea Therapeutics
2018-01-30 – 2020-02-25 · Hypertriglyceridemia, Cardiovascular Diseases
What this study did
Severe Hypertriglyceridemia
NCT05355402 · Ionis Pharmaceuticals, Inc.
2022-05-09 – 2023-12-21 · Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
What this study did
Phase 1 (2)
Other / comorbidity
NCT05579860 · Ionis Pharmaceuticals, Inc.
2022-10-05 – 2023-05-22 · Healthy Participants
What this study did
NCT02900027 · Ionis Pharmaceuticals, Inc.
2016-09 – 2018-04-30 · Elevated Triglycerides (TG)
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Familial Chylomicronemia Syndrome: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Olezarsen (Tryngolza): this drugApprovedRNA / oligonucleotideAPOC3Partial signal
NCT04568434: Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53.
Plozasiran (Redemplo)ApprovedRNA / oligonucleotideAPOC3Partial signal
NCT05089084: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): ARO-APOC3 (Plozasiran) 25 mg -80.1% (IQR -89.9 to -61) | ARO-APOC3 (Plozasiran) 50 mg -77.6% (IQR -87.7 to -48.6) vs Placebo (Pooled) -17.1% (IQR -49.1 to 47)
Volanesorsen (Waylivra)Phase 3RNA / oligonucleotideAPOC3 mRNAReliable signal
NCT02211209: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Placebo 17.6 percent change (95% CI -4 to 39.2) | Volanesorsen -76.5 percent change (95% CI -97.4 to -55.5)
CS-121Phase 1Gene therapy / editingAPOC3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tryngolza (Olezarsen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 3Severe HypertriglyceridemiaActive not recruiting
Est. primary completion 2027-03 · NCT05681351 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Familial Chylomicronemia SyndromeActive not recruiting
Est. primary completion 2027-06 · NCT05185843 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 3Familial Chylomicronemia SyndromeActive not recruiting
Est. primary completion 2028-02 · NCT05130450 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Phase 3Familial Chylomicronemia SyndromeRecruiting
Est. primary completion 2030-08 · NCT07727538 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026ApprovalEuropean Commission approves Tryngolza in severe hypertriglyceridaemia
EU, European Commission · Source ↗
19 May 2025Topline resultPhase 3 Essence (NCT05610280) of olezarsen met its primary endpoint
Ionis Pharmaceuticals · Source ↗